Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04581395 · ClinicalTrials.gov registry record · Phase 3
The Effect of Pretreatment With Roc on Succinylcholine Myalgias
A Phase 3 study of Myalgia, sponsored by Indiana University.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT04581395: Completed Phase 3 study of Myalgia, sponsored by Indiana University.
NCT04581395 is a Phase 3 study of Myalgia that has completed, run by Indiana University. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04581395, a Phase 3 study of Myalgia, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Succinylcholine is a medication (depolarizing muscle relaxant) that is used as part of an anesthetic (going to sleep for surgery). This medication can cause significant muscle soreness. Rocuronium is a medication (non-depolarizing muscle relaxant) that some anesthesia providers believe may reduce muscle soreness caused by succinylcholine if given prior, but this has been controversial. Some anesthesiologists pretreat patients with rocuronium before giving patients succinylcholine, and some do not. The purpose of this study is to examine the effect of pretreatment with rocuronium on muscle soreness associated with succinylcholine administration.
Primary Outcome
The data are reported as pain (scores 1-4) vs. no pain (score 0).
Conditions Studied
Interventions
- OTHER non-pretreated Succinylcholine
- DRUG succinylcholine 1 minute after rocuronium pretreatment
- DRUG succinylcholine 2 minutes following rocuronium pretreatment
Study Locations (1)
Indiana
- indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 3 |
What the finished NCT04581395 record still lists
NCT04581395 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Myalgia appearing as the primary indexed condition, and to 3 interventions - of which non-pretreated Succinylcholine is the first listed.
NCT04581395 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04581395 about?
NCT04581395 is a clinical study titled "The Effect of Pretreatment With Roc on Succinylcholine Myalgias". Succinylcholine is a medication (depolarizing muscle relaxant) that is used as part of an anesthetic (going to sleep for surgery). This medication can cause significant muscle soreness. Rocuronium is a medication (non-depolarizing muscle relaxant) that some anesthesia providers believe may reduce mu...
What is the current status of trial NCT04581395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2020-10-02. Estimated completion is 2023-04-25.
What conditions does trial NCT04581395 study?
This clinical trial studies the following conditions: Myalgia.
What interventions are being tested in trial NCT04581395?
The interventions under investigation include: non-pretreated Succinylcholine (OTHER), succinylcholine 1 minute after rocuronium pretreatment (DRUG), succinylcholine 2 minutes following rocuronium pretreatment (DRUG).
Who is sponsoring clinical trial NCT04581395?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04581395 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04581395's enrollment target sits among peer trials
300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI